After successful screening of patients based on inclusion criteria, we will measure the baseline Hepatic Venous Pressure Gradient. At day 1 patients will undergo complete blood investigation including complete haemogram, kidney function test, liver function test, prothrombin time, AFP (Alfa Feto Protein) level, chest x ray, ultrasonography, fibroscan. Routine complete physical examination will be done.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
220
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Total number of patients who will be Responders.
Responders (Absolute value of HVPG\<12 mm Hg or HVPG≥20% reduction)
Time frame: 3 Months
Total number of patients develop esophageal variceal bleed
Time frame: 3 months
Total number of patients develop PHG (Portal Hypertensive Gastropathy).
Time frame: 3 months
Total number of patients develop GAVE (Gastric Antral Vascular Ectasia).
Time frame: 3 months
Total number of patients develop Gastric Varices.
Time frame: 3 months
Total number of patients develop adverse Events of the study drug
Time frame: 3 months
Improvement in the CTP (Child-Turcotte-Pugh score) score.
Time frame: 3 months
Improvement in the MELD (Model for End Stage liver Disease) score.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.